Targeting a glioblastoma cancer stem-cell population defined by EGF receptor variant III.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Cancer Research

• Publication date

  2014-02-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/0008-5472.CAN-13-1407PMID 24366881PMCID PMC5661963
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• EGFRvIII gene rearrangement is an early event in glioblastoma tumorigenesis and expression defines a hierarchy modulated by epigenetic mechanisms

  2013cited by this paper
• In Situ Analysis of Mutant EGFRs Prevalent in Glioblastoma Multiforme Reveals Aberrant Dimerization, Activation, and Differential Response to Anti-EGFR Targeted Therapy

  2012cited by this paper
• Glioblastoma Stem–like Cell Lines with Either Maintenance or Loss of High-Level EGFR Amplification, Generated via Modulation of Ligand Concentration

  2012cited by this paper
• Epidermal growth factor receptor variant III contributes to cancer stem cell phenotypes in invasive breast carcinoma.

  2012cited by this paper
• Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells

  2011cited by this paper
• Cells of origin in cancer

  2011cited by this paper
• Transdifferentiation of glioblastoma cells into vascular endothelial cells

  2011cited by this paper
• A distinct subset of glioma cell lines with stem cell‐like properties reflects the transcriptional phenotype of glioblastomas and overexpresses CXCR4 as therapeutic target

  2011cited by this paper
• Regulation of glioblastoma stem cells by retinoic acid: role for Notch pathway inhibition

  2011cited by this paper
• Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells

  2011cited by this paper
• Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.

  2010cited by this paper
• Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma.

  2010cited by this paper
• Glioblastoma-derived spheroid cultures as an experimental model for analysis of EGFR anomalies

  2010cited by this paper
• The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation.

  2010cited by this paper
• Neoplastic stem cells: current concepts and clinical perspectives.

  2010cited by this paper
• Rindopepimut, a 14-mer injectable peptide vaccine against EGFRvIII for the potential treatment of glioblastoma multiforme.

  2010cited by this paper
• Integrin alpha 6 regulates glioblastoma stem cells.

  2010cited by this paper
• Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.

  2010cited by this paper
• SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma.

  2009cited by this paper
• ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays.

  2009cited by this paper
• Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma.

  2009cited by this paper
• Identification of CD15 as a marker for tumor-propagating cells in a mouse model of medulloblastoma.

  2009cited by this paper
• EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma.

  2009cited by this paper
• Glioblastoma Formation from Cell Population Depleted of Prominin1-Expressing Cells

  2009cited by this paper
• HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion

  2008cited by this paper
• Cancer stem cells: at the headwaters of tumor development.

  2007cited by this paper
• Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma.

  2007cited by this paper
• A perivascular niche for brain tumor stem cells.

  2007cited by this paper
• CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles.

  2007cited by this paper
• Brain tumor stem cells: identification and concepts.

  2007cited by this paper
• Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13Rα2, gp100 and TRP-2 for immunotherapy

  2006cited by this paper
• Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

  2006cited by this paper
• Somatic stem cells and the origin of cancer

  2006cited by this paper
• Immunohistochemical analysis of the mutant epidermal growth factor, ΔEGFR, in glioblastoma

  2006cited by this paper
• The natural history of EGFR and EGFRvIII in glioblastoma patients

  2005cited by this paper
• Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII

  2005cited by this paper
• Resistance to Tyrosine Kinase Inhibition by Mutant Epidermal Growth Factor Receptor Variant III Contributes to the Neoplastic Phenotype of Glioblastoma Multiforme

  2004cited by this paper
• Immunohistochemical Detection of EGFRvIII in High Malignancy Grade Astrocytomas and Evaluation of Prognostic Significance

  2004cited by this paper
• Identification of human brain tumour initiating cells

  2004cited by this paper
• Molecular structure of double-minute chromosomes bearing amplified copies of the epidermal growth factor receptor gene in gliomas.

  2004cited by this paper
• Expression of constitutively activated EGFRvlll in non‐small cell lung cancer

  2003cited by this paper
• Stem cells, cancer, and cancer stem cells

  2001cited by this paper
• Embryonic stem cell-derived neurogenesis. Retinoic acid induction and lineage selection of neuronal cells.

  2001cited by this paper
• Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas.

  2000cited by this paper
• Immunotoxins with increased activity against epidermal growth factor receptor vIII-expressing cells produced by antibody phage display.

  2000cited by this paper
• A naturally occurring mutant human epidermal growth factor receptor as a target for peptide vaccine immunotherapy of tumors.

  1997cited by this paper
• Transformational and altered signal transduction by a naturally occurring mutant EGF receptor.

  1996cited by this paper
• Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors.

  1995cited by this paper
• Structural alterations of the epidermal growth factor receptor gene in human gliomas.

  1992cited by this paper
• Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts.

  1990cited by this paper

• Blood-tumor barrier organoids recapitulate glioblastoma microenvironment and enable high-throughput modeling of therapeutic delivery

  2025cites this paper
• Comparative efficacy and safety of therapeutic strategies for EGFRvIII positive recurrent glioblastoma

  2025cites this paper
• Tumor heterogeneity and resistance in glioblastoma: the role of stem cells

  2025cites this paper
• Tissue mechanics in tumor heterogeneity and aggression

  2025cites this paper
• CRISPR-Cas9 Gene Editing for Targeting Cancer Stem Cells in Glioblastoma Multiforme

  2025cites this paper
• In Silico Born Designed Anti-EGFR Aptamer Gol1 Has Anti-Proliferative Potential for Patient Glioblastoma Cells

  2025cites this paper
• In Vitro Functional Validation of an Anti-FREM2 Nanobody for Glioblastoma Cell Targeting

  2025cites this paper
• The hidden architects of glioblastoma multiforme: Glioma stem cells

  2024cites this paper
• Expression features of targets for anti-glioma CAR-T cell immunotherapy

  2024cites this paper
• Comprehensive insights into glioblastoma multiforme: drug delivery challenges and multimodal treatment strategies.

  2024cites this paper
• Peptide-Hitchhiking for the Development of Nanosystems in Glioblastoma

  2024cites this paper
• The hope, hype and obstacles surrounding cell therapy

  2024cites this paper
• Targeted immunotherapy to cancer stem cells: a novel strategy of anticancer immunotherapy.

  2024cites this paper
• Insights into Targeted and Stimulus‐Responsive Nanocarriers for Brain Cancer Treatment

  2024cites this paper
• Identification of glioblastoma stem cell-associated lncRNAs using single-cell RNA-sequencing datasets

  2023cites this paper
• Molecular Targeted Therapies in Glioblastoma Multiforme: A Systematic Overview of Global Trends and Findings

  2023cites this paper
• Identification of glioblastoma stem cell-associated lncRNAs using single-cell RNA sequencing datasets

  2023cites this paper
• Improving the efficacy of anti-EGFR drugs in GBM: Where we are going?

  2023cites this paper
• SOX2 in Glioblastoma: Regulation Mechanisms and A Potential Therapeutic Target

  2023cites this paper
• A novel EGFR variant EGFRx maintains glioblastoma stem cells through STAT5.

  2023cites this paper
• Emerging Role of Glioma Stem Cells in Mechanisms of Therapy Resistance

  2023cites this paper
• Systematic Review of Molecular Targeted Therapies for Adult-Type Diffuse Glioma: An Analysis of Clinical and Laboratory Studies

  2023cites this paper
• Shaping the brain vasculature in development and disease in the single-cell era

  2023cites this paper
• CAR T Cell Therapy in Glioblastoma: Overcoming Challenges Related to Antigen Expression

  2023cites this paper
• Increased EGFRvIII Epitope Accessibility after Tyrosine Kinase Inhibitor Treatment of Glioblastoma Cells Creates More Opportunities for Immunotherapy

  2023cites this paper
• Recent advances in drug delivery systems for targeting brain tumors

  2023cites this paper
• Novel Cyclic Peptides for Targeting EGFR and EGRvIII Mutation for Drug Delivery

  2022cites this paper
• EGFR-targeted bacteriophage lambda penetrates model stromal and colorectal carcinoma tissues, is taken up into carcinoma cells, and interferes with 3-dimensional tumor formation

  2022cites this paper
• Phenotypical Flexibility of the EGFRvIII-Positive Glioblastoma Cell Line and the Multidirectional Influence of TGFβ and EGF on These Cells—EGFRvIII Appears as a Weak Oncogene

  2022cites this paper
• Dissecting Stemness in Aggressive Intracranial Meningiomas: Prognostic Role of SOX2 Expression

  2022cites this paper
• Signaling pathways in the regulation of cancer stem cells and associated targeted therapy

  2022cites this paper
• Glioma stem cell signature predicts the prognosis and the response to tumor treating fields treatment

  2022cites this paper
• Quantum dots: The cutting-edge nanotheranostics in brain cancer management.

  2022cites this paper
• NF-κB in neurodegenerative diseases: Recent evidence from human genetics

  2022cites this paper
• Biomanufacturing of glioblastoma organoids exhibiting hierarchical and spatially organized tumor microenvironment via transdifferentiation

  2022cites this paper
• Targeting Glioblastoma Stem Cells to Overcome Chemoresistance: An Overview of Current Therapeutic Strategies

  2022cites this paper
• Can a signature molecular-profile define disparate survival in BRAF-positive Gliosarcoma and identify novel targets for therapeutic intervention?

  2022cites this paper
• Specific Targeting of Cancer Stem Cells by Immunotherapy: A Possible Stratagem to Restrain Cancer Recurrence and Metastasis.

  2022cites this paper
• Glioblastoma mutations alter EGFR dimer structure to prevent ligand bias

  2022cites this paper
• Patient‐individual phenotypes of glioblastoma stem cells are conserved in culture and associate with radioresistance, brain infiltration and patient prognosis

  2022cites this paper
• Celecoxib-Induced Modulation of Colon Cancer CD133 Expression Occurs through AKT Inhibition and Is Monitored by 89Zr Immuno-PET

  2022cites this paper
• Increased replication stress and R-loop accumulation in EGFRvIII-expressing glioblastoma present new therapeutic opportunities

  2021cites this paper
• ANO1 regulates the maintenance of stemness in glioblastoma stem cells by stabilizing EGFRvIII

  2021cites this paper
• Therapeutic approaches to overcome temozolomide resistance in glioblastoma

  2021cites this paper
• Enhancing proteasomal processing improves survival for a peptide vaccine used to treat glioblastoma

  2021cites this paper
• Cripto-1 as a Potential Target of Cancer Stem Cells for Immunotherapy

  2021cites this paper
• Mechanisms of cancer stem cell senescence: Current understanding and future perspectives

  2021cites this paper
• Imaging Metformin Efficacy as Add-On Therapy in Cells and Mouse Models of Human EGFR Glioblastoma

  2021cites this paper
• Glioma Stem Cells as Immunotherapeutic Targets: Advancements and Challenges

  2021influential citation
• Impact of Chaperone-Mediated Autophagy in Brain Aging: Neurodegenerative Diseases and Glioblastoma

  2021cites this paper
• Targeting Cancer Stem Cells by Genetically Engineered Chimeric Antigen Receptor T Cells

  2020cites this paper
• Impairing temozolomide resistance driven by glioma stem‐like cells with adjuvant immunotherapy targeting O‐acetyl GD2 ganglioside

  2020cites this paper
• PARK7 maintains the stemness of glioblastoma stem cells by stabilizing epidermal growth factor receptor variant III

  2020influential citation
• Exploiting the Complexities of Glioblastoma Stem Cells: Insights for Cancer Initiation and Therapeutic Targeting

  2020cites this paper
• Efficacy of osimertinib against EGFRvIII+ glioblastoma

  2020cites this paper
• Molecular Targets for Combined Therapeutic Strategies to Limit Glioblastoma Cell Migration and Invasion

  2020cites this paper
• Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells

  2019cites this paper
• Target selection of CAR T cell therapy in accordance with the TME for solid tumors.

  2019cites this paper
• Prognostic implications of epidermal growth factor receptor variant III expression and nuclear translocation in Chinese human gliomas

  2019cites this paper
• Cancer stem cell immunology and immunotherapy: Harnessing the immune system against cancer's source.

  2019cites this paper
• Pedf derived peptides affect colorectal cancer cell lines resistance and tumour re-growth capacity

  2019cites this paper
• PATH-38. ROSETTE-FORMING GLIONEURONAL TUMOR IS DEFINED BY FGFR1 ACTIVATING ALTERATIONS WITH FREQUENT ACCOMPANYING PI3K AND MAPK PATHWAY MUTATIONS

  2019cites this paper
• EGFRvIII: An Oncogene with Ambiguous Role

  2019cites this paper
• Genetic Abnormalities, Clonal Evolution, and Cancer Stem Cells of Brain Tumors

  2018cites this paper
• Novel therapies hijack the blood–brain barrier to eradicate glioblastoma cancer stem cells

  2018cites this paper
• Immunotherapeutic Approaches to Target Cancer Stem Cell: Progress and Challenges

  2018cites this paper
• The expansion of targetable biomarkers for CAR T cell therapy

  2018cites this paper
• Cancer Stem Cells are Regulated by STAT3 Signalling in Wilms Tumour

  2018cites this paper
• Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics

  2018cites this paper
• Drug delivery challenges and future of chemotherapeutic nanomedicine for glioblastoma treatment

  2018cites this paper
• The Clinical Significance of HPRT as a Diagnostic and Therapeutic Biomarker for Hematological and Solid Malignancies

  2018cites this paper
• Pediatric glioblastoma cells inhibit neurogenesis and promote astrogenesis, phenotypic transformation and migration of human neural progenitor cells within cocultures

  2018cites this paper
• 2 . Twenty-first century epidemiological trends

  2018cites this paper
• EGFR/EGFRvIII Dual-Targeting Peptide-Mediated Drug Delivery for Enhanced Glioma Therapy.

  2017cites this paper
• The EGFR variant III mutant as a target for immunotherapy of glioblastoma multiforme

  2017cites this paper
• 3D Mathematical Modeling of Glioblastoma Suggests That Transdifferentiated Vascular Endothelial Cells Mediate Resistance to Current Standard-of-Care Therapy.

  2017influential citation
• Splice Variants of the RTK Family: Their Role in Tumour Progression and Response to Targeted Therapy

  2017cites this paper
• Molecular signatures linked to stemness and tumorigenesis in tumorspheres from in vitro transformed cells

  2017influential citation
• Cancer stem cell molecular markers verified in vivo

  2017cites this paper
• Clinical Epidermal Growth Factor Receptor Variant III ( EGFRvIII ) Positivity in EGFR-Ampli fi ed Glioblastomas : Prognostic Role and Comparison between Primary and Recurrent Tumors

  2017cites this paper
• SHP2 regulates proliferation and tumorigenicity of glioma stem cells

  2017cites this paper
• Antibody–drug conjugates in glioblastoma therapy: the right drugs to the right cells

  2017cites this paper
• Low Incidence along with Low mRNA Levels of EGFRvIII in Prostate and Colorectal Cancers Compared to Glioblastoma

  2017cites this paper
• Recombinant expression of extracellular domain of mutant Epidermal Growth Factor Receptor in prokaryotic and baculovirus expression systems.

  2017cites this paper
• of Suggests That Transdifferentiated Vascular Endothelial Cells Mediate Resistance to Current Standard-of-Care Therapy.

  2017cites this paper
• A Rational Approach to Target the Epidermal Growth Factor Receptor in Glioblastoma.

  2017cites this paper
• Clinical Applications of Contrast-Enhanced Perfusion MRI Techniques in Gliomas: Recent Advances and Current Challenges

  2017cites this paper
• Therapeutic antibodies against cancer stem cells: a promising approach

  2017cites this paper
• ANTICANCER EFFECT OF BERBERINE: REGULATION OF DEATH SIGNALING PATHWAYS

  2017cites this paper
• Metastasis: an early event in cancer progression

  2017cites this paper
• Targeting Stem Cells in Radiation Oncology.

  2017cites this paper
• Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in EGFR-Amplified Glioblastomas: Prognostic Role and Comparison between Primary and Recurrent Tumors

  2017cites this paper
• Gr upSM Identification of Novel Therapeutic Targets in Glioblastoma

  2017cites this paper
• Anti-EGFRvIII Chimeric Antigen Receptor-Modified T Cells for Adoptive Cell Therapy of Glioblastoma

  2017cites this paper
• Quick Guide to Equations and Assumptions

  2017cites this paper
• Introduction: Cancer Stem Cells

  2017cites this paper
• The anti‐hypertensive drug prazosin inhibits glioblastoma growth via the PKCδ‐dependent inhibition of the AKT pathway

  2016cites this paper
• Recent advances and future of immunotherapy for glioblastoma

  2016cites this paper
• Current Trends in High-Grade Gliomas

  2016cites this paper
• Modeling of Human Vascularized Colon Tumors in Three-dimensional Extracted Extracellular Matrices

  2016cites this paper